Back to mobile site
Get it on Google Play

Telix gets FDA alignment to expand prostate cancer trial to U.S.

July 1, 2026 9:31 PM EDT Send to a Friend
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) announced it has reached alignment with the U.S. Food and Drug Administration to advance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login